カテゴリ： GlobalData, 企業調査, 日本

Astellas Pharma Inc (4503)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：Astellas Pharma Inc (4503) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C11416
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Astellas Pharma Inc (Astellas) is a research based pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises both marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, diseases and disorders of central nervous system (CNS), and metabolic diseases, immunodeficiency diseases, and transplantation. The company is investigating enfortumab vedotin in Phase 2 and Phase 3 clinical trials for the treatment of urothelial cancer; zolbetuximab in Phase 3 clinical trials for the treatment of gastric cancer and gastroesophageal junction cancer; roxadustat in Phase 3 clinical studies for the treatment of patients with anemia associated with chronic kidney disease (CKD) in patients on dialysis and non-dialysis; fezolinetant in Phase 2a clinical trials for the treatment of menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and gilteritinib for the treatment of for acute myeloid leukemia (AML). It operates in the Americas; Europe; and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Astellas Pharma Inc (4503) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Astellas Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Astellas Pharma Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Astellas Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Astellas Pharma Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Astellas Pharma Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Astellas Pharma Inc, Medical Equipment, Deal Details 11
Venture Financing 11
Euroscreen Raises USD17.8 Million in Series B Financing Round 11
Ganymed Pharmaceuticals Secures USD60.74 Million in Venture Funding 13
Partnerships 14
Astellas US and Academy of Oncology Nurse & Patient Navigators (AONN+) Enter into Partnership 14
Medivation and NanoString Technologies Enters into Partnership With Astellas Pharma 15
Qiagen Enters into Co-Development Agreement with Astellas Pharma 16
Astellas Pharma Enters Into Co-Marketing Agreement With Nippon Kayaku For A670 17
Equity Offering 18
Advanced Cell to Raise USD30 Million in Private Placement of Shares 18
Advanced Cell Technology Files Registration Statement For Public Offering Of Securities For US$35 Million 19
Advanced Cell Technology Completes First Tranche Of Private Placement Of Shares For US$1 Million 20
Asset Transactions 21
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 21
Acquisition 22
Astellas Pharma Acquires Ganymed Pharma 22
Astellas Pharma Inc – Key Competitors 24
Astellas Pharma Inc – Key Employees 25
Astellas Pharma Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Joint Venture 34
Recent Developments 35
Financial Announcements 35
Oct 31, 2018: Astellas announce financial results of for the first six months of FY2018 35
Apr 26, 2018: Astellas Reports Financial Results for FY2017 39
Jan 31, 2018: Astellas Reports Financial Results for the First Nine Months of FY2017 41
Oct 31, 2017: Astellas Reports First Half FY2017 Financial Results, Revises Fiscal Year Outlook 43
Jul 28, 2017: Astellas Reports First Quarter FY2017 Financial Results 45
Apr 27, 2017: Astellas Reports Full Year FY2016 Financial Results 47
Jan 31, 2017: Astellas Reports the First Nine Months Financial Results of FY2016 49
Corporate Communications 50
Nov 12, 2018: Astellas names Eloiza Domingo-Snyder to Head of Diversity and Inclusion 50
Sep 18, 2018: Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US 51
Aug 23, 2018: Astellas announces promotion of Rodrigo Fernandez to Vice President, Latin America 52
Jun 08, 2018: Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas 53
May 15, 2018: Astellas Names Bernhardt Zeiher As New Chief Medical Officer 54
Mar 28, 2018: Astellas Appoints Tatjana Dragovic, J.D. Head of Ethics & Compliance 55
Mar 15, 2018: Astellas Names Percival Barretto-Ko President, Americas Operations 56
Mar 13, 2018: Astellas Announces Key Leadership Changes in Legal, Human Resources 57
Jan 31, 2018: Astellas Appoints Kenji Yasukawa as President and CEO 58
Jan 08, 2018: Astellas Announces Leadership Changes in Canada and U.S. 59
Dec 13, 2017: Astellas Appoints Anthony Fiordaliso to Vice President, Americas Finance 60
Dec 04, 2017: Astellas Appoints Joao Carlos de Britto as General Manager of Astellas Farma Brasil 61
Dec 01, 2017: Astellas Announces Personnel Change 62
Nov 01, 2017: Astellas Announces Leadership Changes in U.S. Health Systems Commercial Organization 63
Oct 31, 2017: Astellas Appoints Nate Crisel to Vice President, Real World Informatics & Analytics 64
Oct 30, 2017: Astellas Appoints Gary Thal, M.D., to Vice President, Specialty, Medical Affairs, Americas 65
Aug 24, 2017: Astellas Announces Personnel Changes and Organizational Changes 66
Jun 26, 2017: Astellas Announces Leadership Promotions in Marketing Strategy and US Commercial Organizations 67
May 11, 2017: Astellas Names Shontelle Dodson Senior Vice President and Head of Medical Affairs Americas 68
Apr 28, 2017: Astellas Announces Key Leadership Promotions in Development Organization 69
Apr 27, 2017: Astellas Pharma Announces Changes of Representative Directors and Directors 70
Feb 08, 2017: Astellas Announces Changes in Management Structure and Global Function 72
Feb 08, 2017: Astellas Announces Personnel Changes and Organizational Changes 73
Legal and Regulatory 75
May 31, 2017: Astellas Announces New Global Website Launch 75
Government and Public Interest 76
May 31, 2018: Astellas Oncology C3 Prize Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World 76
Jul 05, 2017: Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year 77
Other Significant Developments 78
Oct 23, 2018: Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App 78
Oct 09, 2018: Astellas details progress and commitment to patients and the community in the company’s americas 2017 corporate social responsibility report card 79
Feb 05, 2018: Astellas Announces Changes in Management Structure, Global Function, and Top Management Committees 80
Feb 05, 2018: Astellas Announces Organizational Changes 81
Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 82
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
Astellas Pharma Inc, Medical Equipment, Key Facts, 2018 2
Astellas Pharma Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Astellas Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Astellas Pharma Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Astellas Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Astellas Pharma Inc, Deals By Market, 2012 to YTD 2018 9
Astellas Pharma Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Euroscreen Raises USD17.8 Million in Series B Financing Round 11
Ganymed Pharmaceuticals Secures USD60.74 Million in Venture Funding 13
Astellas US and Academy of Oncology Nurse & Patient Navigators (AONN+) Enter into Partnership 14
Medivation and NanoString Technologies Enters into Partnership With Astellas Pharma 15
Qiagen Enters into Co-Development Agreement with Astellas Pharma 16
Astellas Pharma Enters Into Co-Marketing Agreement With Nippon Kayaku For A670 17
Advanced Cell to Raise USD30 Million in Private Placement of Shares 18
Advanced Cell Technology Files Registration Statement For Public Offering Of Securities For US$35 Million 19
Advanced Cell Technology Completes First Tranche Of Private Placement Of Shares For US$1 Million 20
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 21
Astellas Pharma Acquires Ganymed Pharma 22
Astellas Pharma Inc, Key Competitors 24
Astellas Pharma Inc, Key Employees 25
Astellas Pharma Inc, Other Locations 28
Astellas Pharma Inc, Subsidiaries 28
Astellas Pharma Inc, Joint Venture 34

List of Figures
Astellas Pharma Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Astellas Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Astellas Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Astellas Pharma Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Astellas Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Astellas Pharma Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Astellas Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Astellas Pharma Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Astellas Pharma Inc (4503)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Kratos Defense & Security Solutions, Inc.：戦略・SWOT・企業財務分析
    Kratos Defense & Security Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kratos Defense & Security Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Avillion LLP：製薬・医療：M&Aディール及び事業提携情報
    Summary Avillion LLP (Avillion) is a provider of drug development services. The company supports pharmaceutical and biotechnology companies, that provides clinical development and approval of late stage pharmaceutical products and candidates. It maintains a business model for the clinical developmen …
  • Ashland Global Holdings Inc (ASH)：企業の財務・戦略的SWOT分析
    Ashland Global Holdings Inc (ASH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Acorda Therapeutics Inc (ACOR)：製薬・医療：M&Aディール及び事業提携情報
    Summary Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. Its portfolio encomppases marketed products for the treatment of multiple sclerosis (MS); and for the management of spasti …
  • MRC Global Inc (MRC)-石油・ガス分野：企業M&A・提携分析
    Summary MRC Global Inc (MRC) is a provider of pipe, valves and fittings. Its product portfolio include carbon steel pipe, carbon steel fittings and flanges, valve automation, stainless and alloy pipe, stainless and alloy fittings and flanges, industrial products, specialty products, oilfield product …
  • ACMAT Corporation：企業の戦略・SWOT・財務情報
    ACMAT Corporation - Strategy, SWOT and Corporate Finance Report Summary ACMAT Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • GlaxoSmithKline Plc (GSK)-医療機器分野：企業M&A・提携分析
    Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respira …
  • Marquette Capital Partners LLC：企業の戦略・SWOT・財務情報
    Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report Summary Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Twist Bioscience Corp (TWST)：医療機器：M&Aディール及び事業提携情報
    Summary Twist Bioscience Corp (Twist Bioscience) is a provider of synthetic DNA Tools. Its silicon-based DNA synthesis platform enables precise synthesis and sequencing process and production of synthetic DNA tools. The company offers its products which include DNA tools for gRNA cloning such as una …
  • Big Rock Brewery, Inc.：企業の戦略・SWOT・財務情報
    Big Rock Brewery, Inc. - Strategy, SWOT and Corporate Finance Report Summary Big Rock Brewery, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Advance Synergy Berhad：企業の戦略・SWOT・財務情報
    Advance Synergy Berhad - Strategy, SWOT and Corporate Finance Report Summary Advance Synergy Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • China Telecom Corporation Limited：企業の戦略・SWOT・財務分析
    China Telecom Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China Telecom Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Chemed Corp (CHE)：企業の財務・戦略的SWOT分析
    Summary Chemed Corp (Chemed) is a diversified company. The company operates through its segments including Vitas and Roto-Rooter. Its Vitas segment provides end-of-life hospice care for heart disease, stroke, multiple sclerosis, lung disease, liver disease, and kidney diseases, among others. Chemed …
  • Hutchison 3G UK Limited：戦略・SWOT・企業財務分析
    Hutchison 3G UK Limited - Strategy, SWOT and Corporate Finance Report Summary Hutchison 3G UK Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Aurizon Holdings Limited：企業の戦略・SWOT・財務情報
    Aurizon Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Aurizon Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Central Electricity Generating Co：企業の発電所・SWOT分析2018
    Central Electricity Generating Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • SDIX LLC：医療機器：M&Aディール及び事業提携情報
    Summary SDIX LLC (SDIX), a subsidiary of OriGene Technologies Inc, is an immuno-solutions company that develops antibody-based solutions. The company provides IVD solutions and premade antibiotics, among others. Its IVD solutions provide co-development of analyte-specific reagents, diagnostic menu e …
  • Emgesa SA ESP-エネルギー分野：企業M&A・提携分析
    Summary Emgesa SA ESP (Emgesa), a subsidiary of Enel, is an energy utility that generates and trades electricity. The company produces power from hydro, coal, and oil and gas; and procures energy from generator and trader agents in the wholesale market. It owns thermal stations: Cartagena and Martin …
  • Aggreko Plc (AGK)-エネルギー分野：企業M&A・提携分析
    Summary Aggreko plc (Aggreko) is a provider of power generation and industrial heating and cooling solutions. It produces power; installs and operates modular and mobile power plants; and develops and rents electric solutions and equipment. The company offers range of diesel and gas power generators …
  • Applied Maths NV-医療機器分野：企業M&A・提携分析
    Summary Applied Maths NV (Applied Maths), a subsidiary of Biomerieux SA is a healthcare technology company that designs, develops and markets various bioscience software products. The company offers software products which include bionumerics, gelcompar, genemaths xt, kodon and bionumerics 2D. Its b …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆